Drug Profile
OBP 801
Alternative Names: OBP-801; YM 753Latest Information Update: 11 Jul 2018
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Developer Astellas Pharma; Kyoto Prefectural University of Medicine; Oncolys BioPharma
- Class Antiglaucomas; Antineoplastics; Cyclic peptides
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Glaucoma
- Discontinued Haematological malignancies
Most Recent Events
- 11 Jul 2018 Phase-I development in Solid tumours is ongoing in USA (IV) (Oncolys BioPharma pipeline, July 2018)
- 11 Jul 2018 Preclinical trials in Glaucoma in Japan (Ophthalmic) (Oncolys BioPharma pipeline, July 2018)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Solid-tumours(Metastatic disease, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (IV)